Cempra Pharmaceuticals Presents New Data on Its Multi-Drug Resistant Anti-Infective Portfolio, Solithromycin (CEM-101) and TAKSTAâ¢ (CEM-102), at The 48th Annual Meeting of The Infectious Diseases Society Of America